BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

SenoSENSE Medical Receives Health Canada Investigational Testing Approval for Densitrode(TM) Technology


2/2/2012 9:24:53 AM

TORONTO--(Marketwire - February 02, 2012) - SenoSENSE Medical Systems Inc., a medical device company engaged in the development of innovative technologies targeted to reducing the impact of breast cancer in younger women, announced today that it has received an Investigational Testing Approval (ITA) from Health Canada. Receipt of the ITA enables the company to initiate clinical testing of SenoSENSE's proprietary Densitrode technology which is planned to begin in February 2012 at Timmins and District Hospital. Dr. Karina Bukhanov, Breast Radiologist with Mount Sinai Hospital Marvelle Koffler Breast Centre and Gattuso Rapid Diagnosis Clinic at Princess Margaret Hospital is the principal investigator for the initial studies.

"The receipt of Investigation Testing Approval for the Densitrode™ beast density sensor represents the first important step in advancing an exciting new technology that we believe offers great promise to identify younger women who are at increased risk of breast cancer, enable proactive intervention to reduce their risk and initiate earlier surveillance to identify cancer at an earlier and more treatable stage," commented Joel Ironstone, President and Chief Executive Officer of SenoSENSE Medical Systems.

About SenoSENSE Medical

SenoSENSE Medical Systems is a Toronto, Ontario-based early stage medical device company developing technology that enables personalized assessment of breast cancer risk in younger women. The company's first product, the Electrical Breast Densitometer, employs proprietary Densitrode technology to assess breast density in combination with other well-accepted breast cancer risk factors. Breast density has emerged as one of the most important determinants of breast cancer risk. A woman with high breast density has 4-6 times higher risk of developing breast cancer than a woman with fatty, low density tissue. Breast cancer is the most prevalent cause of death in women under the age of 50.


Contact:
Joel Weinstein
Marketing/Corporate Development
SenoSENSE Medical Systems Inc.
(508) 877-9025
Email Contact



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES